A randomised placebo controlled double blind clinical trial comparing selenium and pentoxifylline in patients with mild Graves' orbitopathy - EUGOGO study B

Completed

• Conditions: Graves' orbitopathy; Nutritional, Metabolic, Endocrine; Thyrotoxicosis [hyperthyroidism]

• Registration Number: ISRCTN16320108
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02-14
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 156

Inclusion Criteria

1. Graves' hyperthyroidism, euthyroid for at least two months by antithyroid drugs or surgery (at least 6 months if I131 is used)
2. Mild Graves' ophthalmopathy (at least 1 sign), with a disease duration of less than 18 months
3. No past treatment of the ophthalmopathy except for local measures
4. Aged 18 - 70 years

Exclusion Criteria

1. NOSPECS class 2c
2. Proptosis greater than 22 mm
3. Diplopia in primary or reading position and/or ocular torticollis
4. Mono-ocular duction in any direction of less than 20 degrees
5. Optic nerve involvement
6. Pregnancy, drugs/alcohol abuse, severe concomitant illness, no informed consent, use of selenium or pentoxifylline containing preparations

Study & Design

• Study Type: Interventional
• Study Design: Not specified